東華大學圖書館 |

Sustainable development for the healthcare industry = reprogramming the healthcare value chain /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Sustainable development for the healthcare industry/ edited by Pierre A. Morgon.
其他題名:	reprogramming the healthcare value chain /
其他作者:	Morgon, Pierre A.
出版者:	Cham :Springer International Publishing : : 2015.,
面頁冊數:	x, 154 p. :ill., digital ;24 cm.
內容註:	Ch 1 Sustainable development for the healthcare industry: Setting the stage -- Ch 2 Can innovation still be the main growth driver of the pharmaceutical industry? -- Ch 3 The importance of understanding the 'lived experience' of patients in pharmaceutical development programs -- Ch 4 Listening to the voice of the patient to facilitate earlier access to promising medicines: Interview with Sjaak Vink -- Ch 5 Drivers of the Real World Data revolution and the transition to Adaptive Licensing: Interview with Dr. Richard Barker -- Ch 6 Sustainable development for the healthcare industry: Vantage Point from Emerging Economies -- Ch 7 Disease Management in the perspective of sustainable growth in heath care system -- Ch 8 Thoughts on Sustainable Healthcare...in a Patient-Centric Society -- Ch 9 The Biopharmaceutical Industry as part of the solution for healthier, wealthier societies: Interview with Dr. Eduardo Pisani -- Ch 10 Sustainable development initiatives: Examples of successful programs and lessons learned-Interview with Dr. Francois Bompart -- Ch 11 The challenges of Sustainable Development for the Healthcare Industry: An Examination from the Perspectives of Biomedical Enterprises -- Ch 12 Corporation's social responsibility: From the awareness of philanthropy to the demand of implementation-The Case of Expanscience.
Contained By:	Springer eBooks
標題:	Medical economics. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-12526-8
ISBN:	9783319125268 (electronic bk.)

Sustainable development for the healthcare industry = reprogramming the healthcare value chain /
Sustainable development for the healthcare industryreprogramming the healthcare value chain /[electronic resource] :edited by Pierre A. Morgon. - Cham :Springer International Publishing :2015. - x, 154 p. :ill., digital ;24 cm. - Perspectives on sustainable growth,2199-8566. - Perspectives on sustainable growth..

Ch 1 Sustainable development for the healthcare industry: Setting the stage -- Ch 2 Can innovation still be the main growth driver of the pharmaceutical industry? -- Ch 3 The importance of understanding the 'lived experience' of patients in pharmaceutical development programs -- Ch 4 Listening to the voice of the patient to facilitate earlier access to promising medicines: Interview with Sjaak Vink -- Ch 5 Drivers of the Real World Data revolution and the transition to Adaptive Licensing: Interview with Dr. Richard Barker -- Ch 6 Sustainable development for the healthcare industry: Vantage Point from Emerging Economies -- Ch 7 Disease Management in the perspective of sustainable growth in heath care system -- Ch 8 Thoughts on Sustainable Healthcare...in a Patient-Centric Society -- Ch 9 The Biopharmaceutical Industry as part of the solution for healthier, wealthier societies: Interview with Dr. Eduardo Pisani -- Ch 10 Sustainable development initiatives: Examples of successful programs and lessons learned-Interview with Dr. Francois Bompart -- Ch 11 The challenges of Sustainable Development for the Healthcare Industry: An Examination from the Perspectives of Biomedical Enterprises -- Ch 12 Corporation's social responsibility: From the awareness of philanthropy to the demand of implementation-The Case of Expanscience.

This volume addresses the dynamics of sustainable development in the healthcare industry, covering all major aspects of the industry, including R&D, manufacturing, regulation, market access, commercialization, and general management. Healthcare markets are evolving under demographic and economic pressures. In mature markets, patients navigate highly complex provider and cash-strapped payer systems with limited control on healthcare quality and outcomes (as reflected by the absence of correlation between spending and patient satisfaction and outcomes). In developing markets, patients have limited awareness, access and ability to pay for healthcare. The pools of profit will progressively shift from prescription drugs to other product segments and to healthcare delivery, and these shifts will be different by region. As it is dealing with a R&D drought, a revenues deflation induced by patient expiries affecting primary care franchises, a portfolio mix evolution towards specialty care products designed for highly profiled patient populations and backed by complex scientific and medical data, the industry needs to identify which business targets are genuinely attractive for major or new investments. At the same time, development of new products and services must be tackled within the context of environmental sustainability. Rather than focusing on the traditional issues of innovation, cost management, and commercial effectiveness associated with growth, the authors including leading academics and industry insiders explore such emerging topics as: The mutations of the management of innovation, as it remains the DNA of the healthcare industry, driven by patient focus and the trend towards personalized medicine the need to foster patient-centricity along the entire value chain of the healthcare industry and company-wide, starting by listening to the voice of the patient earlier in the lifecycle of drug candidates the broad scope of issues related to improving access to care and disease management, from drug design, to innovative licensing, to valuation based on real-world evidence, to supply and availability so as to ensure optimal access the allocation of educational resources focused on the patient to increase the effectiveness of disease management the preservation of natural resources and the environmental effects of pollution and hazards created by the handling of pharmaceutical products the capacity issues in relation to the size of the medical need and/or of the market demand the private-public partnerships to address the full spectrum of public health issues, from basic patient access to care to managing global health crises, the required organizational and governance evolutions for the healthcare industry to maintain profitable and sustainable growth. Emphasizing environmental, economically, and socially sustainable practices, the authors present a unique, multi-faceted set of perspectives on this vital and rapidly evolving field. They provide a unique vantage point on the reboot the healthcare industry should engage into in order to enhance the sustainability of its business model.

ISBN: 9783319125268 (electronic bk.)

Standard No.: 10.1007/978-3-319-12526-8doiSubjects--Topical Terms:

613524
Medical economics.

LC Class. No.: RA410 / .S87 2015

Dewey Class. No.: 338.473621

Sustainable development for the healthcare industry = reprogramming the healthcare value chain /
LDR:05528nmm a2200325 a 4500 001 1994453
003 DE-He213
005 20150730140502.0
006 m d
007 cr nn 008maaau
008 151019s2015 gw s 0 eng d
020 $a 9783319125268 (electronic bk.)
020 $a 9783319125251 (paper)
024 7 $a 10.1007/978-3-319-12526-8 $2 doi
035 $a 978-3-319-12526-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RA410 $b .S87 2015
072 7 $a KCQ $2 bicssc
072 7 $a MED002000 $2 bisacsh
082 0 4 $a 338.473621 $2 23
090 $a RA410 $b .S964 2015
245 0 0 $a Sustainable development for the healthcare industry $h [electronic resource] : $b reprogramming the healthcare value chain / $c edited by Pierre A. Morgon.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a x, 154 p. : $b ill., digital ; $c 24 cm.
490 1 $a Perspectives on sustainable growth, $x 2199-8566
505 0 $a Ch 1 Sustainable development for the healthcare industry: Setting the stage -- Ch 2 Can innovation still be the main growth driver of the pharmaceutical industry? -- Ch 3 The importance of understanding the 'lived experience' of patients in pharmaceutical development programs -- Ch 4 Listening to the voice of the patient to facilitate earlier access to promising medicines: Interview with Sjaak Vink -- Ch 5 Drivers of the Real World Data revolution and the transition to Adaptive Licensing: Interview with Dr. Richard Barker -- Ch 6 Sustainable development for the healthcare industry: Vantage Point from Emerging Economies -- Ch 7 Disease Management in the perspective of sustainable growth in heath care system -- Ch 8 Thoughts on Sustainable Healthcare...in a Patient-Centric Society -- Ch 9 The Biopharmaceutical Industry as part of the solution for healthier, wealthier societies: Interview with Dr. Eduardo Pisani -- Ch 10 Sustainable development initiatives: Examples of successful programs and lessons learned-Interview with Dr. Francois Bompart -- Ch 11 The challenges of Sustainable Development for the Healthcare Industry: An Examination from the Perspectives of Biomedical Enterprises -- Ch 12 Corporation's social responsibility: From the awareness of philanthropy to the demand of implementation-The Case of Expanscience.
520 $a This volume addresses the dynamics of sustainable development in the healthcare industry, covering all major aspects of the industry, including R&D, manufacturing, regulation, market access, commercialization, and general management. Healthcare markets are evolving under demographic and economic pressures. In mature markets, patients navigate highly complex provider and cash-strapped payer systems with limited control on healthcare quality and outcomes (as reflected by the absence of correlation between spending and patient satisfaction and outcomes). In developing markets, patients have limited awareness, access and ability to pay for healthcare. The pools of profit will progressively shift from prescription drugs to other product segments and to healthcare delivery, and these shifts will be different by region. As it is dealing with a R&D drought, a revenues deflation induced by patient expiries affecting primary care franchises, a portfolio mix evolution towards specialty care products designed for highly profiled patient populations and backed by complex scientific and medical data, the industry needs to identify which business targets are genuinely attractive for major or new investments. At the same time, development of new products and services must be tackled within the context of environmental sustainability. Rather than focusing on the traditional issues of innovation, cost management, and commercial effectiveness associated with growth, the authors including leading academics and industry insiders explore such emerging topics as: The mutations of the management of innovation, as it remains the DNA of the healthcare industry, driven by patient focus and the trend towards personalized medicine the need to foster patient-centricity along the entire value chain of the healthcare industry and company-wide, starting by listening to the voice of the patient earlier in the lifecycle of drug candidates the broad scope of issues related to improving access to care and disease management, from drug design, to innovative licensing, to valuation based on real-world evidence, to supply and availability so as to ensure optimal access the allocation of educational resources focused on the patient to increase the effectiveness of disease management the preservation of natural resources and the environmental effects of pollution and hazards created by the handling of pharmaceutical products the capacity issues in relation to the size of the medical need and/or of the market demand the private-public partnerships to address the full spectrum of public health issues, from basic patient access to care to managing global health crises, the required organizational and governance evolutions for the healthcare industry to maintain profitable and sustainable growth. Emphasizing environmental, economically, and socially sustainable practices, the authors present a unique, multi-faceted set of perspectives on this vital and rapidly evolving field. They provide a unique vantage point on the reboot the healthcare industry should engage into in order to enhance the sustainability of its business model.
650 0 $a Medical economics. $3 613524
650 0 $a Medical care. $3 553082
650 0 $a Sustainable development. $3 528388
650 0 $a Health care reform. $3 814429
650 0 $a Pharmaceutical industry. $3 630829
650 1 4 $a Economics/Management Science. $3 890844
650 2 4 $a Health Care Management. $3 2054807
650 2 4 $a Production/Logistics/Supply Chain Management. $3 1530229
650 2 4 $a Innovation/Technology Management. $3 1565353
650 2 4 $a Sustainable Development. $3 900447
700 1 $a Morgon, Pierre A. $3 2133287
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Perspectives on sustainable growth. $3 2071541
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-12526-8
950 $a Business and Economics (Springer-11643)